Ritodrine HCl

产品说明书

Print
Chemical Structure| 23239-51-2 同义名 : 利托君盐酸盐 ;DU21220 hydrochloride;Ritodrine (hydrochloride);(±)-Ritodrine;NSC 291565;DU 21220;Ritodrine hydrochloride
CAS号 : 23239-51-2
货号 : A444012
分子式 : C17H22ClNO3
纯度 : 99+%
分子量 : 323.815
MDL号 : MFCD01657514
存储条件：

Pure form Keep in dark place,Inert atmosphere,Room temperature

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 115 mg/mL(355.14 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 100 mg/mL(308.82 mM)
动物实验配方：
生物活性
描述 Ritodrine hydrochloride (DU21220 hydrochloride) is a β-2 adrenergic receptor agonist. In treating preterm labour, ritodrine can significantly prolong a short interval more quickly but with relatively more side effects than magnesium sulphate[3]. Multivariable analysis showed that the total dose of ritodrine was significantly associated with pulmonary oedema. Consideration of the total dose of ritodrine hydrochloride is helpful in the management of patients with threatened preterm labour in twin pregnancy[4]. However, long-term tocolysis with intravenous infusion of ritodrine hydrochloride, a betamimetic, can be selected as the first-line tocolytic treatment in Japan[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03298191 Preterm Labor Without Delivery Phase 4 Recruiting May 25, 2018 Egypt ... 展开 >> Mohamed Atef Mohamed Recruiting Sohag, Egypt Contact: mohamed mohamed    +01005537951    mohammedelksoy@yahoo.com 收起 <<
NCT00679705 Healthy Phase 1 Completed - Belgium ... 展开 >> University Hospital Ghent Ghent, Belgium, 9000 收起 <<
NCT02538718 Preterm Labor Not Applicable Recruiting - Korea, Republic of ... 展开 >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 110744 Contact: Joong Shin Park, MD PhD          Seoul Metropolitan Goverment Seoul National University Boramae Medical Center Recruiting Seoul, Korea, Republic of, 156707 Contact: Byung Jae Kim, M.D, Ph.D.       bjkimmd7@snu.ac.kr 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.09mL

0.62mL

0.31mL

15.44mL

3.09mL

1.54mL

30.88mL

6.18mL

3.09mL
参考文献

[1]Onishi H, Sakata O, et al. In vitro and in vivo evaluations of buccal tablet formulations of ritodrine hydrochloride. Biol Pharm Bull. 2015;38(6):919-25.

[2]Sakata O, Onishi H. In vivo absorption study of ritodrine hydrochloride in the buccal administration to rats. Drug Dev Ind Pharm. 2013 Sep;39(9):1414-20.

[3]Li X, Zhang Y, Shi Z. Ritodrine in the treatment of preterm labour: a meta-analysis. Indian J Med Res. 2005;121(2):120-127

[4]Shinohara S, Sunami R, Uchida Y, Hirata S, Suzuki K. Association between total dose of ritodrine hydrochloride and pulmonary oedema in twin pregnancy: a retrospective cohort study in Japan. BMJ Open. 2017;7(12):e018118.

[5]Shigemi D, Aso S, Yasunaga H. Inappropriate use of ritodrine hydrochloride for threatened preterm birth in Japan: a retrospective cohort study using a national inpatient database. BMC Pregnancy Childbirth. 2019;19(1):204.